Santen Pharmaceutical Co., Ltd.

No companywide revenue, EPS, gross margin, or year-over-year financial figures were stated in the provided remarks. On guidance and timing, management said STN1011700 was resubmitted in the U.S. with a PDUFA date set for November 6, the company is aiming for a November price listing for one approved product, Europe launch for the glaucoma ROCK inhibitor program is targeted for this fiscal year, and a third long-term Phase 3 study in Japan will continue. They also said Phase 2/3 work for STN1012700 in China has started, Phase 3 preparation for STN1013800 is underway, and MGD proof-of-concept data are expected within the second quarter.

No CEO remarks were included in the excerpt; the strategic message came from the Chief Medical Officer. The tone was cautiously constructive: the company emphasized continued pipeline progress across multiple geographies and indications, with several near-term catalysts. Management repeatedly stressed moving programs forward as quickly as possible, especially in Japan and China.

No CFO remarks or financial disclosures were included in the excerpt, so there were no reported comments on revenue, margin, cash, or capital allocation. The only hard timing points given were regulatory and development milestones, including the November 6 PDUFA date, a November price listing target, Europe launch target this fiscal year, and MGD data expected in the second quarter. The resubmission details for STN1011700 also noted that the FDA’s non-compliance concern related to contract manufacturing was addressed before the in-depth review could begin.

In Q&A, an analyst asked about timing and next steps for the glaucoma ROCK inhibitor program, and management said it is exploring options to move as expeditiously as possible in Japan while also beginning Phase 1 preparations in China. On the STN1011700 resubmission, management reiterated that the FDA’s letter cited non-compliance related to contract manufacturing, that the company worked with the agency and manufacturer to address requirements, and that it expects the PDUFA date by November 6 at the latest. Management avoided giving more specific timeline commitments beyond that.